NEWS
Go back
ARCHIMED’s FIM Medical becomes the leading developer and distributor of European occupational healthcare devices with its purchase of Vistec GmbH
October
23,
2025
In a pivotal strategic development, ARCHIMED’s FIM Medical has acquired Vistec GmbH, a leading company specialized in vision screening devices for the occupational health sector, from 22 Ventures GmbH, a German investment firm.
Vistec substantially boosts FIM Medical’s global revenue and makes it the largest medical device player in European occupational healthcare diagnostics.
The purchase makes FIM Medical Europe’s largest developer and distributor of European occupational healthcare devices by revenue and substantially increases the company’s international sales, which span Europe, the US and Canada. Vistec founded in 2000, is based in Olching, Germany, near Munich.
Prior to this acquisition, FIM Medical, based in Lyon and founded in 1986, was already the leader in the French occupational healthcare market.
“ARCHIMED and FIM are exploring more acquisitions to expand products and geographical reach.” “We’ve substantially strengthened our leadership of European occupational healthcare with the purchase of Vistec,” says Marie-Ange Derei, FIM Medical’s CEO. “This is the kind of smart, next-level move that partnering with ARCHIMED permits.”
Both FIM and Vistec medical devices fit into the rising trend of healthcare providers prioritizing preventive measures in the workplace, offering increasingly regular checkups focused on the early identification of potential health risks.
FIM Medical offers a diversified, technologically-advanced range of products in the fields of vision, hearing and respiratory care, leveraging patented proprietary systems in its devices and software to drive growth. Vistec offers cutting-edge vision testing solutions, including vision screening devices, peripheral vision equipment and psychometric testing systems. It significantly expands FIM Medical’s in-house manufacturing capacity.
Since its acquisition by ARCHIMED in October 2024, FIM has taken multiple steps to increase its value. These initiatives have driven strong double-digit sales and profit growth.
The company has strengthened its leadership team, consolidated and expanded its market position in France, and expanded distribution partnerships across Europe and the US.
Partnering with ARCHIMED has accelerated FIM Medical’s R&D, with the company launching products like Visiolite 4K, which analyses potential vision problems in just five minutes, and ADL Connect, a particularly comprehensive testing system for auditory issues. FIM Medical has developed an especially strong R&D pipeline for further product improvement and expansion.
“Buying Vistec aligns with our plans to expand FIM internationally, both organically and through acquisitions”.
Antoine Faguer, Partner at ARCHIMED
FIM Medical was acquired by ARCHIMED through its MED Rise Fund. MED Rise is ARCHIMED’s small-cap fund dedicated to buyouts within the global healthcare industries. MED Rise, three times oversubscribed, closed in April 2024, reaching its hard cap of €400 million.